Clinical Trials in Poland — Country Dashboard | 2,702 EU Studies

Filter these 2,702 trials by condition, phase, sponsor and more.

Open in Search →

2,702 Registered trials

1,005 Recruiting

1,520 Completed trials

692 Sponsors active

1,789 Research sites

Phase III

Phase II

Phase III: 1475 Phase II/III: 128 Phase II: 720 Phase I/II: 91 Phase III/IV: 24 Phase IV: 63 Phase I: 64 Phase I (Other): 79 Phase I (FiH): 45 Other: 13

Oversight events in trials active here:

87 serious breaches 586 temporary halts 52 urgent safety measures 65 unexpected events 112 corrective measures across 331 trials

View oversight register →

Top conditions

Non-small cell lung cancer 82 Non-small cell lung cancer metastatic 35 Crohn's disease 31 Systemic lupus erythematosus 29 Colitis ulcerative 27 Myasthenia gravis 27 Asthma 25 Rheumatoid arthritis 21 Ovarian cancer 20 Diffuse large B-cell lymphoma 19 Multiple sclerosis 19 Breast cancer 17

Top sponsors

Merck Sharp & Dohme LLC 160 AstraZeneca AB 138 F. Hoffmann-La Roche AG 137 Janssen - Cilag International 104 Novartis Pharma AG 79 Pfizer Inc. 65 AbbVie Deutschland GmbH & Co. KG 63 Sanofi-Aventis Recherche & Developpement 63 Bristol-Myers Squibb Services Unlimited Company 59 Amgen Inc. 52 Eli Lilly & Co. 50 Takeda Development Center Americas Inc. 46

Cities with most trials

All 255 cities →

All trials — page 29

2,702 total

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Phase III Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymph… BeOne Medicines AG
Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center,… Recruiting

2023-509235-39-00 Phase IV Nicotine dependence Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada…
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Phase III Major Depressive Disorder Cybin IRL Limited
TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting

2024-519917-72-00 Phase III Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloido… Alnylam Pharmaceuticals Inc.
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Phase III Mild to moderate Alzheimer’s Disease Bristol-Myers Squibb Services Unlimited Company
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Phase III Moderate to Severe Plaque Psoriasis Bristol-Myers Squibb Services Unlimited Company
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Phase III Previously Untreated Advanced or Metastatic Non-Squamous Non… F. Hoffmann-La Roche AG
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Phase II Moderate to severe atopic dermatitis Novartis Pharma AG
A study to investigate the efficacy and safety of SAR444336 in adults with microscopic colitis in clinical remission. Recruiting

2024-519495-83-00 Phase II Digestive system diseases Sanofi-Aventis Recherche & Developpement
A Phase 2 Study of the Effects and Safety of PF-07328948 in Adults with Heart Failure (BRANCH-HF) Recruiting

2024-518438-94-00 Phase II Heart failure Pfizer Inc.
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and… Recruiting

2024-517140-65-00 Phase I/II Multiple Myeloma (MM). AbbVie Deutschland GmbH & Co. KG
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease Recruiting

2024-514110-12-00 Phase I (FiH) Thyroid Eye Disease Amgen Inc.
A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting

2025-520461-41-00 Phase II Rheumatoid Arthritis (RA) Artiva Biotherapeutics Inc.
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 Phase III Major Depressive Disorder Neurocrine Biosciences Inc.
FORTIFY – Focused Orticumab Research for Treating inflammation in Coronary Arteries Recruiting

2025-520464-17-00 Phase II Atherosclerotic Cardiovascular disease Abcentra LLC
A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s… Recruiting

2024-519623-23-00 Phase III Venous leg ulcer Mediwound Ltd.
Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting

2024-516924-32-00 Phase III Neovascular Age-Related Macular Degeneration (nAMD) F. Hoffmann-La Roche AG
C4951063: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting

2024-517121-10-00 Phase III Menstrual Migraine Pfizer Inc.
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 Phase II platinum-resistant advanced high-grade epithelial ovarian, p… AbbVie Deutschland GmbH & Co. KG
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Phase III Hidradenitis suppurativa (HS) MoonLake Immunotherapeutics AG
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy. Recruiting

2025-521640-38-00 Phase III Focal onset seizures or primary generalized tonic-clonic sei… Praxis Precision Medicines Inc.
The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement Recruiting

2023-509111-89-00 Phase III Systemic mastocytosis with a slow course and involvement of … Medical University Of Gdansk
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II Relapsed or Refractory B-Cell Malignancies BeOne Medicines AG
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Phase III Type 2 diabetes Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH

Showing 673–696 of 2,702 trials

← All countries